Novavax (NASDAQ: NVAX) reported Q4 EPS of ($0.29), $0.15 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $5.9 million versus the consensus estimate of $8.07 million.

2016 Anticipated Events:

• Announce top-line data from Resolve, the Phase 3 pivotal RSV F Vaccine in older adults in third quarter of 2016; and
• Announce top-line data from the Phase 2 RSV F Vaccine rollover trial in older adults in the second half of 2016.

For earnings history and earnings-related data on Novavax (NVAX) click here.